Grant: Operating Grant: Epigenetics Clinical Translation
University of Calgary
$852,300.00
MGMT promoter methylated breast cancer: An opportunity for a targeted treatment with alkylating agent temozolomide in combination with existing breast cancer therapeutics.
FY 2018-19
Summary
Breast cancer (BC) is responsible for 25% of all female cancer diagnoses annually, affects 1 in 8 women, and is the 2nd leading cause of cancer death among Canadian women. Temozolomide (TMZ) is a well-tolerated oral chemotherapy used to treat brain cancers and its efficacy is linked to down regulation of a protein named MGMT. MGMT is involved in the the repair of DNA damage and is expressed in normal human cells; however, in cancer cells the modification (methylation) of the MGMT gene promoter leads to down regulation of the MGMT protein. MGMT when present, repairs the damage caused by TMZ promoting cancer survival and when absent allows cellular death. Down regulation of MGMT has been consistently noted in certain subtypes of BC, and we hypothesize that TMZ may be a novel, targeted, therapeutic option that can be combined with other DNA targeting therapies such as PARP inhibition in patients whose tumors apriori fail to express MGMT.
Department
Program
Operating Grant: Epigenetics Clinical Translation
Recipient
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
391910
Name
Morris Donald G
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Clinical
Prcname2
Operating Grant : Epigenetics Clinical Translation
Projecttitle
MGMT promoter methylated breast cancer: An opportunity for a targeted treatment with alkylating agent temozolomide in combination with existing breast cancer therapeutics.
Programtype2
Operating Grants
Orgnameinp2
University of Calgary
Cihramount2
$852,300
Cihrequipment2
$0
Programname2
Operating Grant: Epigenetics Clinical Translation
Keyworddelim
Epigenetics; Mgmt; Olaparib; Parp Inhibition; Targeted Treatment; Temozolomide; Triple Negative Breast Cancer
Abstract
Breast cancer (BC) is responsible for 25% of all female cancer diagnoses annually, affects 1 in 8 women, and is the 2nd leading cause of cancer death among Canadian women. Temozolomide (TMZ) is a well-tolerated oral chemotherapy used to treat brain cancers and its efficacy is linked to down regulation of a protein named MGMT. MGMT is involved in the the repair of DNA damage and is expressed in normal human cells; however, in cancer cells the modification (methylation) of the MGMT gene promoter leads to down regulation of the MGMT protein. MGMT when present, repairs the damage caused by TMZ promoting cancer survival and when absent allows cellular death. Down regulation of MGMT has been consistently noted in certain subtypes of BC, and we hypothesize that TMZ may be a novel, targeted, therapeutic option that can be combined with other DNA targeting therapies such as PARP inhibition in patients whose tumors apriori fail to express MGMT.
Competitiondate
201810
Approvedterm2
4 yrs 0 mth
Pinamesdelim
Morris, Donald G; Verma, Sunil
Approvedterm
4 ans 0 mois
Cihrcontribution2
~ $852,300~ $0~
